

# Stefan Hinz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8705293/publications.pdf>

Version: 2024-02-01

17  
papers

429  
citations

1039406

9  
h-index

1125271

13  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1018  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. <i>Carcinogenesis</i> , 2013, 34, 2361-2369.	1.3	107
2	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2473-2485.	1.9	86
3	PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1190-1201.	1.9	63
4	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. <i>Cancer Letters</i> , 2015, 358, 59-66.	3.2	48
5	Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 12.	3.5	27
6	Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer. <i>PLoS ONE</i> , 2013, 8, e58037.	1.1	25
7	Hijacking EMT: Better Fat Than Dead. <i>Cancer Cell</i> , 2019, 35, 1-2.	7.7	22
8	Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1032-1043.	1.9	19
9	Breast-Specific Molecular Clocks Comprised of <i>ELF5</i> Expression and Promoter Methylation Identify Individuals Susceptible to Cancer Initiation. <i>Cancer Prevention Research</i> , 2021, 14, 779-794.	0.7	11
10	Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies. <i>Cancer Research</i> , 2014, 74, 1747-1747.	0.4	11
11	Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand-Addicted Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 936-947.	1.9	4
12	Deep proteome profiling of human mammary epithelia at lineage and age resolution. <i>IScience</i> , 2021, 24, 103026.	1.9	3
13	Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models. <i>Clinical Cancer Research</i> , 2014, 20, B30-B30.	3.2	3
14	Deep Proteome Profiling of Human Mammary Epithelia at Lineage and Age Resolution. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
15	Abstract 2071: Addition of antiangiogenic agents enhances nab-paclitaxel antitumor activity in experimental pancreatic cancer. , 2013, , .		0
16	Abstract 1025: Antitumor activity of nintedanib (BIBF 1120), a triple angiokinase inhibitor, in combination with gemcitabine in experimental pancreatic cancer. , 2014, , .		0
17	Protocol for computationally evaluating the loss of stoichiometry and coordinated expression of proteins. <i>STAR Protocols</i> , 2022, 3, 101182.	0.5	0